INI World Report > Uncategorized > CHINA’S RESEARCH THIEVERY AND THE FRAMING OF AN HONEST MAN ~
CHINA’S RESEARCH THIEVERY AND THE FRAMING OF AN HONEST MAN ~
(A decade ago we published the outrageous and illegal treatment of Dr. French Anderson, one of the world’s leading scientific researchers. Here we have a two-part update on the story from Mark Adams, who has followed the story closer than anyone.)
CHINESE SPIES STEAL MIRACLE VACCINE FROM USA COMPANY
by National Security Commentator Mark Adams
Part One: The Set Up
China has stolen a vaccine developed in the U.S. – completely safe, yet so powerful a single dose prevents immediate animal death followed by full recovery after exposure to lethal radiation providing it is made available within 24 hours after initial exposure. China’s villainous spy scheme would never have succeeded were it not for rampant corruption in American law enforcement, specifically the Los Angeles Sheriff’s Dept. (LASD), and in the American courts.
During the last century the world witnessed the awesome destructive power of nuclear weapons.
While a nuclear bomb blast-wave is dramatically destructive, a far more deadly effect results from radiation poisoning. After the 1945 bombings of Hiroshima and Nagasaki it was radiation poisoning that claimed the vast majority of the victims who died a slow lingering death with horrific symptoms including burning skin, severe headaches, intense nausea, vomiting blood and bloody diarrhea. Thousands of people later died from radiation-induced cancer.
Dr. French Anderson, the inventor of the vaccine, is a pioneer geneticist widely known as the Father of Gene Therapy he being the first person to successfully use gene therapy to treat a 4-year-old child suffering from severe combined immunodeficiency, popularly known as the “bubble boy disease.”
Upon graduating Anderson went to Great Britain and worked in the lab of Francis Crick who won the Nobel Prize for deciphering the double helical structure of DNA. Upon returning to the United States he attended Harvard Medical School where he received his M.D. magna cum laude.
Anderson then went to the National Institutes of Health (NIH) working in the lab of Marshall Nirenberg who won the Nobel Prize for deciphering the genetic code. Nirenberg rewarded Anderson for his prodigious efforts by allowing him to make the first public presentation of the final genetic code before a FASEB science convention in Atlantic City.
It should be noted that in addition to his intellectual prowess Anderson also has a fifth degree black belt in taekwondo. In 1981, he became the team physician for the National Taekwondo Team, and was also the team physician at the 1988 Olympics in Seoul Korea when taekwondo became an Olympic sport. He is also an accomplished track runner.
During his career Anderson has published over 400 medical articles, and holds 35 patents related to gene therapy. Additionally he owns several patents in conjunction with the Physics Department at Cal Tech for his landmark contributions to microfluidics – “lab on a chip” technology.
In addition to providing fundamental advances in gene therapy Anderson invented, patented, and had the exclusive right to bring to market a revolutionary cancer treatment drug termed Interleukin-12 (IL-12) that dramatically reduces the damaging side effects of radiation and chemotherapy in cancer patients thus permitting much greater dosages of irradiation by reducing its toxic side effects.
According to the National Cancer Institute, Anderson’s IL-12 discoveries would “have a high likelihood of success that could clearly change the course of conventional cancer therapy.”
In 2003 the drug was valued at $9 billion, but the side effects and suffering it can relieve for millions of cancer patients cannot be measured in dollars alone.
Further testing revealed that IL-12 – by then available as the recombinant protein, HemaMax™,when provided within 24 hours after exposure to lethal radiation, a single dose resulted in complete recovery. Here is where this landmark discovery was published.
HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates
Needless to say these astounding findings indicate that HemaMaxTM is an ideal candidate for a frontline vaccine to save human lives from the deadly effects of lethal radiation exposure in case of a nuclear event.
After leaving NIH Anderson became a Professor at the University of Southern California (USC) Keck School of Medicine and Director of the Gene Therapy Laboratories. He had come to USC in 1992 along with his wife, Kathryn, so that she could accept the position of Chief of Surgery at the Los Angeles Children’s Hospital. In 2005, she became the first female President of the American College of Surgeons in its then nearly 100 year history.
While at NIH Anderson founded a gene therapy biotech, Genetic Therapy Inc. (GTI), which was sold to Novartis in 1996. In 1999, he founded a second biotech company, Farmal Inc., to develop the cancer treatment drug in partnership with USC.
Farmal was founded by Anderson and Robert Monks, who had invested heavily in Anderson’s first company, GTI, and had made a great deal of money when GTI was bought by Novartis for $325 million. Therefore, when Anderson found himself with no company ties, he accepted Monks’ offer of forming a new biotechnology company, Farmal Inc. The company was founded on June 24, 1999.
Anderson’s primary research program at NIH, as well as after he moved to USC, was in gene therapy. But he had one project at NIH to develop live animal assays to search for specific factor(s) in the serum that could produce an important clinically-relevant result. Accordingly, the first 3 clinical conditions to be examined in experimental models by Farmal were to be:
-
Irradiation injury – by repairing radiation side effects, much higher doses of irradiation could be used in cancer treatment thereby improving cancer cure rates.
-
Traumatic injury – enormous amounts of time are lost as patients slowly recover from traumatic injuries.
-
Sepsis – improving recovery rates from sepsis, a major cause of death, would be significant.
By 2001, all the variables had been optimized and Anderson had obtained reproducible positive results regarding the irradiation experiments: The serum from a previously irradiated animal could rescue another lethally irradiated animal.
Since Farmal had developed a reproducible assay for a lethal irradiation rescue factor (LIRF), and could obtain large quantities of serum, the next step was to identify the serum factor(s) that constituted LIRF. Dr. Yi Zhao, a Chinese nationalist who was a senior research scientist in Anderson’s USC lab, was very anxious to be involved and became a Farmal business partner from the beginning.
Eventually, IL-12 was identified as the main component of LIRF. Monks was, of course, becoming very excited at this point. LIRF, now identified as IL-12, was a potentially billion-dollar cancer therapeutic drug. Talks began of greatly expanding Farmal, looking for other deep-pocket investors, even carrying out an initial public offering (IPO).
In November, 2002, Anderson turned the entire IL-12 (LIRF) program over to Zhao to finish up, while he began meeting with potential investors, develop an expanded business plan, and continued to develop a mouse assay for the second targeted clinical condition: finding a traumatic injury recovery factor (TIRF). He was successful in obtaining positive results in mice, but no purification of the factor(s) from serum was carried out.
A Board Meeting in December, 2002, set the stage for Farmal’s expansion which was to be followed by a March 11-12, 2003, Board Meeting when the major decisions relating to expansion and fund raising would be made. Instead, Monks abruptly closed down Farmal on March 13.
As it turns out Zhao intentionally caused Farmal to crash by fraudulently telling Anderson and the Farmal investors just before the Board Meeting of March 11-12, 2003, that her IL-12 studies had failed. Fifteen long years later, in December, 2018, forensic investigator, Daniel Haste, found the conclusive emails from Zhao that proved that the sabotage of Farmal was planned ahead of time and carefully orchestrated.
In a critical March 3, 2003 email Zhao tells Anderson, “All the results I get so far are negative. … I feel so bad.”
The result was that on March 13, 2003 at 8 am Monks called Anderson and told him, “I am pulling the plug on Farmal.”
Three events happened in October/November 2002. Besides obtaining the first IL-12 positive result and Anderson giving the IL-12 project over to Zhao, Farmal obtained an additional investor, Frank Baxter, and so Monks organized Farmal shares along proper business criteria on October 28, 2002, with Monks and Baxter getting the bulk of the ownership, while Anderson was reduced from 25% to 7.02% and Zhao reduced from 25% to 1.67%. Zhao was enraged and felt betrayed. It is speculated that at that point she made the ultimate decision not to wait to steal the IL-12 protocols until they were further developed, but to steal them immediately and take them to China.
Further revelations from forensic investigator Daniel Haste turned up IL-12 related patents filed by Zhao:
“Haste told the Courier that he discovered clear evidence that Zhao founded her Chinese company to pursue work based on her Asian patent for IL-12, which is nearly identical to an earlier ‘Provisional Patent’ filed in the U.S. on which both Zhao and Anderson are named as authors. Just weeks after the provisional patent lapsed in America, Zhao filed one in China based on the work done under Anderson at USC; this time, sans Anderson’s name.”
Haste also discovered a United States patent filed by Zhao that lists her home address even though she was a research scientist at USC.
Both the 2003 China patent application and the 2004 “secret” American patent application list Yi Zhao and another Chinese scientist, Tiang Chao Chen as the sole inventors.
In 2011 Zhao founded Kang Litai Pharmaceutical Hi-tech Zone. Her company Kangli Tai Pharmaceutical won the National Major Technology Project under the category “Major
New Drug Creation”.
Forensic investigator Haste also discovered a Chinese trade journal article that features Zhao’s KLT Pharmaceutical company that was posted on July 2017 by Qingdao Creator in Finance. In the article Zhao makes some outrageous remarks:
“Zhao also talked about the competitor in the United States. This invention was discovered through her research in the University of Southern California. ‘It is owned by USC. At that time, the lawyer who helped me draft the patent application discovered this technology. [????] Thus a company was set up to begin the research and development.’
“Zhao chose to bring it back to China to conduct technology transfer to benefit domestic patients. Zhao said, ‘Although it is based on the same patent, we have no relationship with each other.’” [!!!!]
Nota Bene:
1) The article stipulates that: “It (the IL-12 anticancer drug which Zhao rebranded as KLT-1101) is owned by USC.” Zhao has no licensing agreement with USC to manufacture and sell IL-12 (now rebranded as KLT- 1101) in China or anywhere else.
2) The article states: “Zhao chose to bring it back to China to conduct technology transfer to benefit domestic patients.” This is not technology transfer; it is outright technology theft, a nefarious practice that China is well known for.
3) The article continues: Zhao said, “Although it is based on the same patent, we have no relationship with each other.” This statement is absurd. Zhao conjures up ludicrous semantics in an attempt to escape the plain fact that she stole Anderson’s and USC’s intellectual property rights for what she describes as a blockbuster anti-cancer drug.
An August 21, 2019, China article, announced that Zhao’s company won first prize in the national finals of the “Maker in China Competition.”
Other evidence not discovered until 2018 and 2019 further explained the sudden failure of Farmal. Zhao had developed and carried out an economic espionage plan in which she secretly lied to the investors that IL-12 was a total failure, causing the investors to immediately pull all funding. Additionally Zhao did something outright despicable: she inveigled her teenage daughter, YH, to accuse Anderson of sexually molesting her when she was 13 years old.
A 2024 Court Petition explained it like this:
When Petitioner Anderson discovered a potential billion-dollar cancer treatment drug, Zhao chose to steal it and take it to China. She was unsuccessful until she had her then 17-year-old daughter claim that Petitioner Anderson had sexually molested her when she was 13. That accusation, supported by an altered sting meeting recording, resulted in Anderson’s arrest, conviction, and a 14 year prison sentence. Once Petitioner Anderson was imprisoned, Zhao took the cancer treatment and gene therapy discoveries together with trade secrets to China where she has been honored with several national awards for her patriotism.
Coming up PART TW0: The Framing of French Anderson.
Attorney Charles D. Harrison explained to the Beverly Hills Courier:
“There’s no doubt in my mind that Dr. Anderson is completely and factually innocent of what he was charged with. His work was stolen. The reason behind the charges that were brought were to steal his intellectual property that he was developing, basically while he was the leader in the field of gene therapy. But because he was the leader in the field, they couldn’t just steal it, because he would be able to stop it. So basically, these false charges were concocted against him.”
